| HOME >> MEDICINE >> TECHNOLOGY |
TABLE 94 FDA-APPROVED FISH ANALYSIS TESTS 135
TABLE 95 ROCHE SALES BY DIVISION, 2010 ($ MILLIONS) 137
TABLE 96 ROCHE COMPANION DIAGNOSTICS CURRENTLY ON THE MARKET OR IN LATE
DEVELOPMENT FOR BREAST CANCER 137
TABLE 97 GENOMIC MARKET LEADERS 138
TABLE 98 GENOMIC TESTING MARKET FOR BREAST CANCER, THROUGH 2016 ($ MILLIONS) 139
TABLE 99 ONCOTYPE DX SALES, THROUGH 2016 ($ MILLIONS) 140
TABLE 100 QUANTITATIVE FLUORESCENCE DIAGNOSTIC TESTING MARKET FOR BREAST
CANCER, THROUGH 2016 ($ MILLIONS) 142
TABLE 101 RESULTS OF A SURVEY BY MEDCO AND THE AMERICAN MEDICAL ASSOCIATION,
2009 160
LIST OF FIGURES
SUMMARY FIGURE GLOBAL MARKET FOR PREDICTIVE BREAST CANCER DIAGNOSTIC AND
DRUG TECHNOLOGIES, 2010–2016 ($ MILLIONS) 6
FIGURE 1 GLOBAL BREAST CANCER INCIDENCE AND MORTALITY, 2008 (THOUSANDS) 63
FIGURE 2 ESTIMATED GLOBAL INCIDENCE OF BREAST CANCER, 2010–2016 65
FIGURE 3 U.K. ESTIMATED INCIDENCE OF BREAST CANCER, 2010–2016 (THOUSANDS) 68
FIGURE 4 GERMAN ESTIMATED INCIDENCE OF BREAST CANCER, 2010–2016 (THOUSANDS) 70
FIGURE 5 CHINESE ESTIMATED INCIDENCE OF BREAST CANCER, 2010–2016 (THOUSANDS) 71
FIGURE 6 INDIA ESTIMATED INCIDENCE OF BREAST CANCER, 2010–2016 (THOUSANDS) 72
FIGURE 7 U.S. ESTIMATED INCIDENCE OF BREAST CANCER, 2010–2016 (THOUSANDS) 77
FIGURE 8 GLOBAL PHARMACEUTICAL SALES, 2010–2016 ($ MILLIONS) 103
FIGURE 9 BREAST CANCER THERAPY SALES, 2010–2016 ($ MILLIONS) 106
FIGURE 10 BREAST CANCER DRUG MARKET, 2010 AND 2016 ($ MILLIONS) 107
FIGURE 11 U.S. PERSONALIZED MEDICINE MARKET, 2010–2016 ($ MILLIONS) 117
FIGURE 12 U.S. PERSONALIZED MEDICINE DIAGNOSTIC TESTS AND TARGETED THERAPIES
MARKET, 2010–2016 ($ MILLIONS) 118
FIGURE 13 NEXT-GENERATION CANCER D
'/>"/>
| SOURCE Reportlinker Copyright©2012 PR Newswire. All rights reserved |